Miracor Diagnostics, Inc. Discloses Interim Data Demonstrating A Strong Trend Toward A Larger Infarct Size-Reduction At Four Months In Patients Treated With Its PICSO® Impulse System To Treat Severe Heart Attack Patients Post-Primary PCI

VIENNA--(BUSINESS WIRE)--Miracor Medical Systems GmbH announced today that it has completed four months’ follow-up of patients enrolled in its “Prepare RAMSES” clinical trial of its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). Interim data from early results indicate a strong trend towards a larger reduction in infarct size at four-month follow-up for patients receiving the PICSO therapy in complement with primary PCI as compared to a historical control group. A total of 30 patients have successfully enrolled in the clinical trial, with no device-related adverse events. (Click here for video animation of PICSO®.)

Help employers find you! Check out all the jobs and post your resume.